Acknowledgements | One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT · Acknowledgements

Acknowledgements

CC BY 4.0 · National Institute for Health and Care Research · approximately 18 min read

We thank the patients who participated in this trial and staff at the participating centres and at ICR-CTSU; we also thank FAST-Forward Trial Management Group members past and present, and the Independent Data Monitoring Committee and Trial Steering Committee for overseeing the trial (listed in Appendix). The FAST-Forward Trial was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Programme – HTA (UK) (09/01/47), with programme grants from Cancer Research UK to support the work of ICR-CTSU (C1491/A15955; C1491/A25351). We acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London, UK). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

TABLE 30 Centre staff who participated in the FAST-Forward Trial – current principal investigators, past principal investigators, main co-investigators and trials teams (including physicists, radiographers, nurses and data managers)

Centre no	Centre name	Centre staff
01	Royal Marsden Hospital Sutton	Dr N Somaiah^a, Dr A Kirby^a, Dr I Locke, Dr D Tait, *Professor J Yarnold*^a, R Colgan, L Gothard, C Lucy
02	Royal Cornwall	Dr D Wheatley^a, Professor D Radstone, Dr A Thomson, n Ashley, S Eloi, A Griffiths, J Kingston, N Simpson
03	University Hospital of North Midlands	Professor AM Brunt^a, Dr D Gahir, Dr A Jegannathen, L Contoret, M Evans, K Glover, A Myatt, R Smith
03a/10c	Stafford General Hospital	Dr A Jegannathen, Dr L Pettit, Dr C Brammer, C Harvey, A Myatt, L Verueco
04	Derriford Hospital, Plymouth	Dr U Panwar, Dr S Dubey, *Dr S Kelly* (RIP), N Blacker, L Cadmore, H Congdon, I Harvey
05^a	Norfolk and Norwich Hospital	Dr D Geropantas, Dr A Bulman, *Dr A Harnett*^a, S Barber, M Bloomfield, E Malone, J Platt
05a^a	James Paget Hospital	Dr S Down, *Dr A Harnett*^a, A Brooks, J Harman
05b/09b^a	Queen Elizabeth Hospital, Kings Lynn	Dr M Daly, R Lee, H Webb
06^a	Bristol Haematology and Oncology	Dr C Comins, *Dr A Bahl*, Dr S Masson, Dr N Thanvi, H Appleby, A Lowe, H Saldanha, V Lee
06a^a	Weston General Hospital	Dr T Wells, *Dr M Tomlinson*, K Owens, H Lloyd-Jones, G Saunders
07^a	Royal Shrewsbury Hospital	Dr L Pettit, *Dr R Agrawal, Dr H Abel Gadir, Dr S Khanduri*, S Jose, S Potts, A Welsh
08	Royal Devon + Exeter Hospital	Dr J Forrest, Dr A Goodman^a, *Dr A Hong*, Dr D Hwang, K Baines, A Betts, T Lawless, S Scrutton
08a^a	North Devon District Hospital	Dr J Forrest, *Dr D Hwang*, R Holbrook, S Ley, L Van Koutrik
09^a	Addenbrookes Hospital	Professor C Coles^a, Dr L Hughes-Davies, *Dr C Wilson*, A Bates, C Philpott, C Spain, B Stratton, N Twyman, J Wilkinson
09a^a	Hinchingbrooke Hospital	Dr S Russell, V Goss, R Kurian, S Miller
09c^a	West Suffolk Hospital	Dr M Moody, Dr C Woodward, S Hale
09d^a	Bedford Hospital	Dr S Smith, V Bastion, G Lubimbi, A Willis, J Valentine
10	New Cross Hospital	Dr R Allerton, Dr C Brammer, *Dr M Churn*^a, Dr L Pettit, Dr P Ramachandran, R Horton, M James-King
10a/50a	Kidderminster Hospital	Dr M Churn^a, S Stringer, H Tranter
10b^a	Russell’s Hall	Dr R Allerton, Dr G Georgiev, Dr P Ramachandra, K Kanyi, K McGarry, A Watts
11^a	Southend University Hospital	Dr H Algurafi, Dr W Ella, *Dr A Robinson*, T Davies, A McPherson, L Romero, S Shibu-Thomas
11a^a	Basildon Hospital	Dr H Swinburn, *Dr W Ella*, C McCormick
12	Clatterbridge Cancer Centre	Dr S Tolan, *Dr I Syndikus*^a, Dr N Thorp, S Green, K Hughes, H Mayles
12a^a	Warrington Hospital	Dr I Syndikus^a, L Lee, C Lowthian, R Madew
12c^a	St Helens + Whiston	Dr R Sripadam, N Hornby
12d	University Hospital, Aintree	Dr P Robson, L Beresford
12e^a	Countess of Chester	Dr A Hall, S Bennett, E Gallimore, M Moffit, J Prince
13	Velindre Cancer Centre	Dr H Passant^a, Dr J Abraham, *Professor P Barrett-Lee*, Dr A Borley, Dr T Howe, Dr R Stevens, M Jenkins, S Slade, A Weaver, O Woodley
14^a	Royal Surrey County Hospital	Dr R Laing, Dr A Franklin, Dr A Neal, Dr S Whittaker, L Adams, M Flavin, B Moloney-Oates, A Tindall
15^a	Essex County Hospital	Dr M Mukesh, Dr V Loo, *Dr P Murray*, K Cooke, C Driscoll
16	Beatson West of Scotland Cancer Centre	Dr A Alhasso^a, Professor P Canney, Dr G Fraser, Dr G Lumsden, Dr M Rizwanullah, A Armstrong, J Fleming, T Ibotoye, A Leonard, M McJury, C Seager, V Withers
16a	Royal Alexandra Hospital	Dr A Alhasso^a, P Eaddy, E MacLeod
16b	Forth Valley Hospital	Dr H Marashi, Dr I Rabnawaz, F Johnston, L Prentice, A Scott
16c	Wishaw Hospital	Dr J Hicks, *Dr M Rizwanullah*, K Douglas
16d^a	New Victoria ACH	Dr D Ritchie, Dr J Ansari, E Moody
16e	Hairmyres Hospital	Dr J Hicks, *Dr G Dunn*, L Devlin, L Glass
16f^a	Crosshouse Hospital, Kilmarmock	Dr G Lumsden, K Bain, C Burns, P Cannon
17^a	Singleton Hospital, Swansea	Dr M Rolles, Dr C Askill, *Dr D Pudney*, Dr R Taylor, E Brinkworth, H Cheley, S Foyle, E Harris, N Viney, J Williams
18	Cheltenham General Hospital	Dr J Bowen^a, Dr K Benstead, Dr R Counsell, Dr S Elyan, R Bakawala, N Bulmer, J Chittock, J Kukielska, A Skelton, M Tan
18a/50	Worcester Royal Infirmary	Dr M Churn^a, *Dr J Bowen*^a, Dr R Counsell, D Bak, A Holdsworth, J Tyler
18b^a	Hereford County Hospital	Dr D Nelmes, *Dr S Guglani*, J Birch, M Evans, G Horsfield
19	Royal Preston	Dr M Hogg
19c	Blackpool Victoria Infirmary	Dr F Danwata, *Dr A Hindley*, Dr S Susnerwala, E Davies, S Lancaster, L Smith
19d	Royal Lancaster Infirmary	Dr D Williamson, *Dr G Skailes*, C Bartlett, A Fielding
20^a	Queens Hospital, Romford	Dr E Sims, Dr C Bridgewater, *Dr M Quigley*, Dr E Staples, T Mills-Baldock, J Cook
21	Peterborough Hospital	Dr C Jephcott, Dr C Round, Dr S Treece, K Cavanagh, C Chisenga, M Cowen
22	Weston Park Hospital, Sheffield	Dr M Hatton, Dr O Din, Dr C Lee, G Brown, J Conway, L Fiorentino, J Swinscoe
23^a	Royal Sussex County Hospital	Dr D Bloomfield^a, Dr S Mitra, Dr A Nikapota, Dr R Simcock, Dr S Westwell, P Frattaroli, A Hewines, J Tremlett
23a^a	Worthing Hospital	Dr SY Sham, *Dr A Nikapota, Dr S Mitra*, S Funnell, J Gilbert
23b^a	Eastbourne Hospital	Dr S Westwell, K Jones-Skipper
24	Guys Hospital	Professor E Sawyer^a, Dr L Brazil, Dr S Harris, Professor A Tutt, G Keunzig, C Thomas
25^a	Ipswich Hospital	Dr R Venkitaraman, *Dr L Sherwin*, C Mackenzie, P Ridley, M Riley
26^a	Glan Clwyd Hospital	Dr J Bishop, G Davies, S Owen, V Saul
26a^a	Wrexham Maelor Hospital	Dr W Soe, Dr J Bishop, Dr N Ghosal, J Stockport
26b^a	Ysbyty Gwynedd Hospital	Dr J Bishop, D Thomas, L Williams.
27	Queen Elizabeth Hospital, Birmingham	Dr A Stevens, *Dr MS Anwar*, Dr D Spooner, S Manolopoulos, R Shingler
27a^a	Sandwell Hospital	Dr D Spooner, D Devonport
27b^a	City Hospital. Birmingham	Dr D Spooner, D Devonport, B Gammon
27c	Manor Hospital, Walsall	Dr S Yaha, *Dr MS Anwar*, J Fletcher
28	Charing Cross Hospital	Dr S Cleator^a, *Dr C Lowdell*, P Dunn, S McInerney
28a^a	Ealing Hospital	Dr O Hatcher, *Dr C Lewanski*, S Magwaro, D Murati, K Watson
28b	West Middlesex Hospital	Dr P Riddle, Dr R Ahmad, J Swallow
29	Mount Vernon Hospital	Dr C Westbury, *Dr M Ah-See*, Dr A Makris, Dr P Ostler, Dr N Shah, Dr N Thanvi, T Chalk, S Hasan, E Windmill
29a^a	Luton and Dunstable University Hospital	Dr A Vinayan, *Dr M Ah-See*, A Rafiq, M Sarte
30^a	Royal United Hospital, Bath	Dr M Beresford, Dr A Jenner, Dr S Mancero, Dr S Manson, Dr H Newman, T Allen, C Milsom, T Tylee, S Whittle
31	Queen Alexandra Hospital, Portsmouth	Dr K Bradley, Dr JD Dubois, Dr A Suovuori, R Baker, K Haselip, N Rivington
32	Torbay District General Hospital	Dr A Goodman^a, Dr P Bliss, M Allison, P Bowen, S Chamberlain, I Koehler
33	Southampton General Hospital	Dr C Crowley, Dr J Marshall, Dr S Raj, C Britton, E Cooper, K Meeking, K Stevens
33a^a	Salisbury Hospital	Dr C Crowley, J Attlee, S Strong-Sheldrake
33b^a	Royal Hampshire County Hospital	Dr S Raj, J Conti, V Corner, J Smith
34	Royal Berkshire	Dr R Davis, Dr J Adams, *Dr J Barrett*, Dr C Charlton, J Jones, P Pabari, E Vowell
34a^a	Wexham Park Hospital	Dr R Davis, *Dr J Adams*, Dr S Inayat, N Barnes, S Das, D Mciver, J Weerasinghe
35	St Bartholomew’s Hospital	Dr V Wolstenholme, Dr C Cottrill, Dr N Patel, Dr K Tipples, F Bibi, H Payne, A Pena-Remorin, A Sivajothi, E Tutor
36	St James’ University Hospital, Leeds	Dr S Kumar, Dr I Chaudhuri, S Hartup, A Henson, J Lilley, P Shuttleworth
36a^b	Pinderfields Hospital, Wakefield	Dr S Kumar, J Ball, S Buckley, C Hirst
36b^b	Bradford Royal Infirmary	Dr E Thomas, R Benton, K Cockroft, H Inman, H Robertshaw, J Sewell
36c^b	Huddersfield Royal Infirmary	Dr N Roberts, M Brady, S Dale, D Melia, S Mellor
37	University Hospital of Coventry and Warwickshire	Dr D Hrouda, Dr L Fresco, Dr C Irwin, *Dr N Walji*, Dr J Wordling, S Manolopoulos, K Sanders
37a^a	George Eliot Hospital, Nuneaton	Dr S Lupton, Dr L Fresco, J Lake
37b^a	Warwick Hospital	Dr N Walji, J Harris, L Maher
37c/50b	Alexandra Hospital, Redditch	Dr M Churn^a, Dr D Hrouda, Dr C Irwin, H Hodson, A Morgan
38	Musgrove Park, Taunton	Dr M Varughese, *Dr J Graham*, S Mahoney
38a	Yeovil District Hospital	Dr U Barthakur, J McCrory, K Rennie
39	Lincoln County Hospital	Dr A Chaudhuri, *Dr E Murray*, Dr T Sreenivasan, O Francis, V Longdon, A Sloan
39a	Pilgrim Hospital, Boston	Dr A Chaudhuri, *Dr E Murray*, A Kirkby
40	Northampton General Hospital	Dr R Agrawal, Professor H Eldeeb, *Dr C Macmillan*, A Kempa, M Polnik, R Tighe, N Whilde
41	James Cook University Hospital	Dr B Sethugavalar, *Dr J Hardman*, Dr JCM Van der Voet, H Curtis, E Thompson
41a	University Hospital of North Tees	Dr E Thompson, *Dr N Storey*, Dr A Rathmell, L Poole
42	Western General Hospital, Edinburgh	Dr C Bedi, Dr T Evans, Professor I Kunkler, Dr F Yuille, R Allan, L Carruthers, L Primrose
42a	Borders General Hospital	Dr C Bedi, M Tolson
42b	Dumfries and Galloway Hospital	Dr A Hennessy, *Dr T Evans*, J Duignan
42c	Queen Margaret Hospital, Dunfermline	Dr M MacLennan^a, Dr A Stillie, *Dr T Evans*, F Adam
42d	St John’s Hospital, Livingstone	Dr F Yuille, R Allen, A Clark
43	Belfast City Hospital	Dr H McCarty, Dr J Clarke, *Dr G Hanna*, Dr L Mulholland, D Irvine, O Stewart, G Totton
44^a	University College London Hospitals	Dr G Blackman, Dr A Cassoni, Dr M Gaze, *Dr M McCormack*, Dr J Tobias, R Patel, S Wickers
45^a	Poole Hospital	Dr J Brady, Dr A Chakrabarti, Dr P Crellin, N Gurung, D Forster, F Mellor, B Troke, L Varnham
46	Leicester Royal Infirmary	Dr K Kancherla, C Belcher, J Potterton, S Wright
47^a	Churchill Hospital, Oxford	Dr S Oliveros, *Dr B Lavery*, N Ann, C Hector, M Flavin, G Samkange
48^c	Ninewells Hospital, Dundee	Dr D Adamson, A Black, G Georgiev
49^c	Nottingham City Hospital	Dr P Lawton, Dr M Griffin, P Dawson, S Dennis, S Fleet
49a^c	Kings Mill Hospital	Dr M Griffin, D Nash

Independent Data Monitoring Committee members: Professor M Sydes (Chair), Professor S Bentzen, Professor J Staffurth (past member: Professor I Turesson)

Independent Trial Steering Committee members: Professor M Mason (Chair), Dr D Gilbert, Dr V Cosgrove, Professor P Poortmans, Professor D Sebag-Montefiore (past members: Dr J Barrett, Professor S Bentzen)

Trial Management Group members: Dr A Alhasso, A Armstrong, Professor J Bliss, Dr D Bloomfield, Dr J Bowen, Professor AM Brunt, Mr C Chan, H Chantler, Dr M Churn, Dr S Cleator, Professor C Coles, Dr E Donovan, H Fleming, Dr D Gahir, Dr D Glynn, Professor S Griffin, J Haviland, Professor P Hopwood, Dr A Kirby, J Kirk, Professor C Kirwan, Dr M MacLennan, Z Nabi, J Patel, Professor E Sawyer, J Sinclair, Dr N Somaiah, M Sydenham, Dr I Syndikus, J Tremlett, Dr K Venables, Dr D Wheatley, Professor J Yarnold (past members: Dr R Agrawal, Dr J Barrett, Professor P Barrett-Lee, Dr P Bliss, Ms L Ciurlionis, Professor J Dewar, Dr P Dyson, Dr S Guglani, Dr H Mayles, D Megias, C Morris, Dr H Passant, C Rawlings, Dr A Robinson, Professor M Sculphur, Dr E Staples, M Wilcox, R Zotova)

Institute of Cancer Research – Clinical Trials and Statistics Unit staff: J Adkins, S Atkins, J Barnett, L Colby, L Courtney, G Dower, M Emson, C Griffin, J Haviland, R Kaggwa, J Kidd, L Lloyd, K Mertens, J Mills, J Morden, A Obabumoye, D Patel, J Patel, J Prince, S Simmons, E Simms, L Stones, G Sumo, M Sydenham, J Bliss

Radiotherapy Quality Assurance team: D Eaton, D Megias, Z Nabi, R Simoes, Y Tsang, K Venables, R Zotova

Contributions of authors

Adrian Murray Brunt (https://orcid.org/0000-0002-4797-5097) (Chief Investigator) contributed to the conception and design of the study, responsible for oversight throughout the trial, interpretation of the results and writing of the report.

John R Yarnold (https://orcid.org/0000-0002-9010-1854) (Chief Investigator) contributed to the conception and design of the study, responsible for oversight throughout the trial, interpretation of the results and writing of the report.

Duncan A Wheatley (https://orcid.org/0000-0002-1919-5114) (Chief Clinical Co-ordinator) contributed to the conception and design of the study, responsible for oversight throughout the trial, interpretation of the results and writing of the report.

Judith M Bliss (https://orcid.org/0000-0001-7957-7424) (Trial Methodology Lead) contributed to the conception and design of the study, provided oversight and guidance for trial management and analyses throughout the trial, interpretation of the results and writing of the report.

Joanne S Haviland (https://orcid.org/0000-0001-5728-3636) (Principal Statistician) contributed to the conception and design of the study, conduct of the trial, responsible for the analysis and interpretation of the results and writing of the report.

Jaymini Patel (https://orcid.org/0000-0001-5690-8630) (Trial Statistician) was responsible for the analysis and interpretation of some of the results and contributed to the writing of the report.

Mark A Sydenham (https://orcid.org/0000-0002-9157-9710) (Trial Manager) contributed to the design of the study, managed the study and data collection at ICR-CTSU, conduct of the trial, interpretation of the results and writing of the report.

David J Bloomfield (https://orcid.org/0000-0003-3639-7065) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Charlie Chan (https://orcid.org/0000-0002-4140-7590) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Suzy Cleator (https://orcid.org/0000-0003-3859-7888) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Charlotte E Coles (https://orcid.org/0000-0003-4473-8552) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Ellen Donovan (https://orcid.org/0000-0003-1692-1587) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Andrew Goodman (https://orcid.org/0000-0002-2463-5129) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Penelope Hopwood (https://orcid.org/0000-0001-8978-0936) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Anna M Kirby (https://orcid.org/0000-0002-5528-1669) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Cliona C Kirwan (https://orcid.org/0000-0002-1725-4790) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Elinor Sawyer (https://orcid.org/0000-0001-8285-4111) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Navita Somaiah (https://orcid.org/0000-0003-4609-0518) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

Isabel Syndikus (https://orcid.org/0000-0001-5781-2067) (Trial Management Group member) contributed to the design of the study, conduct of the trial, interpretation of the results and writing of the report.

David Glynn (https://orcid.org/0000-0002-0989-1984) (Health Economics team) (Health Economics team) contributed to the conception, design and analysis of the health economics study and the writing of the health economics chapter.

Susan Griffin (https://orcid.org/0000-0003-2188-8400) (Health Economics team) contributed to the conception, design and analysis of the health economics study and the writing of the health economics chapter.

Zohal Nabi (https://orcid.org/0000-0003-3564-1177) (RTTQA team) contributed to the design, conduct and analysis of the QA programme and the writing of the QA chapter.

Karen Venables (https://orcid.org/0000-0001-8829-2367) (RTTQA team) contributed to the design, conduct and analysis of the QA programme and the writing of the QA chapter.

Helen Fleming (https://orcid.org/0000-0002-3524-5652) (Patient and Public Involvement) was the patient advocate member of the TMG, and provided guidance for study documentation and reports and writing of the report.

All authors reviewed and approved the final report.

Publications and presentations

Zotova R, Tsang YM, Conibear J, Miles E. Field-based and volume-based PTVs as plan evaluation structures in the UK FAST-Forward breast trial. Poster presentation, ECCO conference, Amsterdam, September 2013. Radiother Oncol 2013;106(S2):S122 (PD-0317).

Brunt AM, Yarnold JR, Wheatley D, Somaiah N, Kelly S, Harnett A, et al. Bliss on behalf of the FAST-Forward Trial Management Group. Acute skin toxicity reported in the FAST-Forward Trial (HTA 09/01/47): a phase III randomised trial of 1-week whole breast radiotherapy compared to standard 3 weeks in patients with early breast cancer. Poster presentation at NCRI conference, Liverpool, 2–5 November 2014.

Zotova R, Yarnold JR, Wheatley D, Griffin C, Brunt M. Results from the radiotherapy quality assurance programme for the FAST-Forward breast trial. Abstract submission for ESTRO 2015 conference. Radiother Oncol 2015;115(S1):S209–S210(PD-0430).

Brunt AM, Wheatley D, Yarnold JR, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 2016 Jul;120(1):114–8. Epub 2016 Apr 1.

Megias D, Sydenham M, Wheatley D, Maclennan M, Spezi E, Brunt AM. Variability of contouring using the ESTRO guideline for elective breast cancer radiotherapy. Oral presentation at ESTRO conference, Vienna, May 2017. Radiother Oncol 2017;123(S1):S136–S137(OC-0265).

Brunt AM, Haviland JS, Sydenham MA, Alhasso A, Bloomfield D, Chan C, et al. OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiother Oncol 2018 April;127(S1):S311–S312. https://doi.org/10.1016/S0167-8140(18)30905-8

FAST-Forward phase III randomised controlled trial of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Oral presentation at ESTRO 37 conference, Barcelona, 23 April 2018. Late Breaking Abstract OC-595.

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Oral presentation at NCRI conference, Glasgow, UK, 5 November 2018.

Hypofractionation for whole breast irradiation in 5 days (Fast Forward Trial). Oral presentation at ASTRO conference, USA, 22 October 2018.

Hypofractionated Whole Breast Radiation Regimens. Oral presentation at ASTRO conference, USA, 18 September 2019.

Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield D, et al. on behalf of the FAST-Forward Trial Management Group. FAST-Forward phase III multicentre non-inferiority randomised controlled trial of 1- versus 3-week hypofractionated breast radiotherapy: 5-year results for efficacy and late normal tissue effects. Lancet 2020;395:1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6

Brunt AM, Haviland JS, Wheatley DA, Yarnold JR. Breast cancer radiation therapy – Authors’ reply. Lancet 2020;396:1559–60. https://doi.org/10.1016/S0140-6736(20)32320-5

Paradigm shift: the role of hypofractionated breast radiotherapy. Oral presentation at UK Association of Breast Surgeons hypofractionation webinar, UK, 26 May 2020.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward). Oral presentation at Virtual Oncology Global webinar Conference organised by Memorial Sloan Kettering, USA, 28 May 2020.

FAST-Forward and beyond. Oral presentation at the CONNECT SENATURK meeting on ‘Hypofractionated radiotherapy in breast cancer: now even shorter’ on 13 June 2020.

NCRI Virtual Webinar titled – Radiotherapy research in the UK: What’s new? Oral presentation of FAST-Forward Trial results, 16 July 2020.

Update on FAST-Forward Trial: Oral presentation at UK Association of Breast Surgeons Webinar Series titled ‘Interesting perspective on patient management since COVID-19 and update on radiotherapy changes’ on 22 September 2020.

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results for efficacy and late normal tissue effects. Oral presentation at UK Royal College of Radiologists consensus meeting, 15 October 2020.

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Invited speaker presentation by Murray Brunt in the ‘Cancer Breakthough’ session at ASTRO 2020 on 25 October 2020. Selected from best of ESTRO 2020.

Who should have the FAST-FORWARD 5 Fraction Radiotherapy Schedule? Oral presentation at virtual 8th UKBCG annual meeting, 20 November 2020.

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results for efficacy and late normal tissue effects. Oral presentation at virtual ESTRO 39 conference, 30 November 2020. Abstract number E20-2292/OC-0610.

Shortening breast radiotherapy to 1 week, FAST-Forward to implementation. Oral presentation at Edinburgh Breast Cancer Special Symposium, 27 February 2021.

Oral presentation of FAST-Forward Trial results at annual international BIR Annual Radiotherapy and Oncology Meeting 2021, 26 March 2021.

Oral presentation of FAST-Forward Trial results in the Breast Cancer Session at the Virtual UK Oncology Forum 2021, 21 October 2021.

Brunt AM, Haviland JS, Kirby AM, Somaiah N, Wheatley D, Bliss JM, Yarnold JR. 5-fraction radiotherapy for breast cancer: FAST-Forward to implementation. Clin Oncol (R Coll Radiol) 2021;33(7):430–9. https://doi.org/10.1016/j.clon.2021.04.016

Wheatley D, Haviland J, Patel J, Sydenham M, Alhasso A, Chan C, et al. on behalf of the FAST-Forward Trial Management Group. First results of FAST-Forward phase 3 RCT Nodal Sub-Study: 3-year normal tissue effects. Oral presentation at ESTRO conference, Copenhagen, 7 May 2022. Abstract E22-2401.

Ethics statement

FAST-Forward was approved by the London-Brighton and Sussex Research Ethics Committee (REC) (previously named South East Coast – Kent REC then South East Coast – Brighton and Sussex REC) on 2 September 2011 (11/LO/0958).

Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to anonymised data may be granted following review. Trial documentation including the protocol are available at www.icr.ac.uk/fastforward (last accessed 20 May 2022).

Disclaimers

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Attribution. Adrian Murray Brunt; Joanne S Haviland; Duncan A Wheatley; Mark A Sydenham; David J Bloomfield; Charlie Chan et al. (2023). One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT. National Institute for Health and Care Research. Copyright © 2023 Brunt et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK597550. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.